Welcure Drugs And Pharmaceuticals Surges To Upper Circuit On Completing Rs 299.91 Cr Order In Q1FY26

Shares of Welcure Drugs & Pharmaceuticals surged approximately 5% on Tuesday, 8th July, from the previous closing price of Rs 11.77 to an upper circuit limit and an intra-day high of Rs 12.35. The company's market capitalization stands at Rs 135.95 crore with a 52-week high of Rs 15.89.

The company achieved seven export-sourcing assignments during the first quarter of FY 2025-26, which are valued at a total of Rs 299.91 crore. For these transactions, the company served exclusively as a procurement agent, earning a fixed commission of 5%. This commissioned structure illustrates that Welcure has shifted its attention toward expanding revenue streams that do not generate debt for the company, as it incurs zero risk from logistics or inventory.

Welcure noted that the export assignments were integral to the company's operations and had been disclosed to the Bombay Stock Exchange, thus abiding by SEBI's Listing Obligations and Disclosure Requirements (Regulation 30). The company continues to report a debt-free status and has reaffirmed that there are no equity or debt instrument arrangements pertaining to these transactions. The commission income will be recognized under Ind AS 115 guidelines, which is upon receipt or dispatch of goods.

As of June 30, 2025, Welcure Mycorrhizal Inoculant Ltd notified the stock exchanges that they had received two new export orders totalling Rs 85.6 crores-each order worth Rs 42.8 crores from Giant Exim and Ravina International. The new contracts are expected to improve the margins of the current quarter due to the contribution from incremental dispatches.

These transactions are announced subsequent to another important milestone that was disclosed on June 18, when the company obtained a global sourcing mandate of Rs 517 crore from Thailand-based Fortune Sagar Impex Company Ltd. This engagement, placed under an Ex-Works structure, will be performed on a call-off basis. The completion deadline is set for September 30, 2026. Responsibility for packaging and labeling, freight, insurance, regulatory clearances, and compliance will be the buyer's responsibility. Welcure Projects anticipates earning a fee income of approximately Rs 25.85 crore from this service in FY 2025-26.

As of now, Welcure has fully executed the sourcing for seven overseas clients in Q1FY26, which include Gyandevi Export, Ravina International, Megh Mani International, Giant Exim, Sakalchand Manilal & Co, Shree Kalbadevi Exim, and Maa Shakti Exports. The payment statuses for these contracts are mixed and range between fully paid, partially paid, advance payments, and letters of credit received, which signify trust in the company's operational efficiency.

In addition, the company anticipates finalizing new export-sourcing agreements exceeding Rs 20 crore in value for the current quarter, pending standard business conditions, after engaging in preliminary negotiations with other buyers.

Welcure Drugs & Pharmaceuticals Ltd., established in 1992, has developed into a reputable player in the pharmaceutical industry, engaged in the manufacturing and trading of healthcare formulations. The company's sustained domestic and international market presence is a result of its service-oriented and asset-light growth strategies, alongside its commitment to quality, compliance, and global partnerships.